Valneva reported positive Phase II results this week for its GlaxoSmithKline-partnered C. difficile vaccine candidate, saying the shot proved to be "highly immunogenic" while also offering a good safety and tolerability profile.
Researchers are starting a 9-month study of breast cancer patients using the Apple Watch to capture basic health data alongside treatment information and various aspects of patient health. The study uses an app that was developed by behavioral health tech company Polaris Health.
Collaborating with academia has been de rigueur in the pharma world for years, but it's a different game these days. Recognizing that scientists on both sides of the divide can't be distant neighbors anymore, drugmakers and academics are invading each other's personal space, even working side-by-side in the same labs. They're learning unexpected things about their counterparts. And they're coming to terms with the inherent conflict between research for curiosity's sake and research for the market.
Seattle's Presage Biosciences has in-licensed Phase I oral cancer drug voruciclib from India's Piramal Enterprises to test its intratumoral microinjection platform, which the company says can accelerate drug development.
Israel's Oramed has brought its oral insulin capsule into China, Hong Kong and Macau, signing an agreement this week worth up to $50 million with the Chinese Hefei Tianhui Incubator of Technologies for exclusive rights to market the treatment in those three locations.
After being exposed as a fraud and convicted of embezzling research funds, Hwang Woo Suk immediately began to work his way back from the disgrace. Now, he's eyeing the launch of a large animal cloning operation in China that aims to produce a million cloned cows to satisfy the country's hunger for mass quantities of high quality beef.
Roche is joining forces with Upsher-Smith on a Phase II therapy with potential in inflammatory disease, in-licensing the drug with plans to flesh out its promise before taking the plunge on late-stage development.
Adaptimmune is tapping a small, Seattle-based biotech for the gene-editing skills needed to develop off-the-shelf T-cell immunotherapies to fight cancer.
Researchers at Cornell University are developing a method to detect stroke in less than 10 minutes using only a drop of blood.
MediSapiens has provided Helsinki University Central Hospital with a bioinformatics platform to support the personalization of leukemia care. The system is designed to help physicians find the best treatment for each patient--and funnel data gained in the field back to support drug R&D initiatives.